Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19462560 | 0.72 | NOS3 (0.40) | SMN1; SMN2MEN1MAPK1KMT2AADORA2A | |
| SCHEMBL30329688 | 0.72 | NOS3 (0.40) | SMN1; SMN2MEN1MAPK1KMT2AADORA2A | |
| SCHEMBL10483989 | 0.72 | MC4R (0.42) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9884955 | 0.71 | SMN1; SMN2 (0.49) | STK17ASMN1; SMN2NPY1RSYKCAMK2D | |
| SCHEMBL27929805 | 0.69 | ALDH1A1 (0.43) | KARS1MEN1GAAKMT2A | |
| SCHEMBL19030966 | 0.69 | LOX (0.48) | STK17AKARS1CAMK2DCYP2D6 | |
| SCHEMBL29714427 | 0.67 | LOX (0.45) | SMN1; SMN2MEN1MAPK1KMT2AADORA2A | |
| SCHEMBL19755849 | 0.67 | LOX (0.45) | SMN1; SMN2MEN1MAPK1KMT2AADORA2A | |
| SCHEMBL10847759 | 0.67 | CYP3A4 (0.42) | STK17ASUV39H2CAMK2DMEN1KMT2A | |
| SCHEMBL10483887 | 0.67 | MC4R (0.45) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283389-A1 | IMPROVED PROCESS FOR MAKING CROTONYLAMINOPYRIDINIES | INTERVET INC. (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2017109027-A1 | IMPROVED PROCESS FOR MAKING CROTONYLAMINOPYRIDINES | INTERVET INTERNATIONAL B.V. (NL) | 2017-06-29 | — | — | WO | disclosed |
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2621903-A1 | N-HETEROARYL COMPOUNDS | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | STK17A 3855/4885SMN1; SMN2 4016/4885NPY1R 3888/4885 |
| US-20200283389-A1 | IMPROVED PROCESS FOR MAKING CROTONYLAMINOPYRIDINIES | CROCC, DHPS, NPEPPS | STK17A 1878/4885SMN1; SMN2 768/4885NPY1R 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.